SCHEMBL8740219

SCHEMBL8740219

CC(=O)c1ccc(OC(C)C)c(Nc2nc(-c3ccccn3)cs2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 7/20 0.59
CSNK2A1 P68400 2/20 0.53
MITF O75030 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
CSNK2A2 P19784 1/20 0.51
CSNK2B P67870 1/20 0.51
CCR6 P51684 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.49
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 1/20 0.49
ALDH1A1 P00352 1/20 0.49
MAPT P10636 1/20 0.49
HTT P42858 1/20 0.49
KMT2A Q03164 1/20 0.49
KDM4A O75164 1/20 0.48
KDM4B O94953 1/20 0.48
KDM5B Q9UGL1 1/20 0.48
MDM4 O15151 1/20 0.48
MDM2 Q00987 1/20 0.48
OPRK1 P41145 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6118313 0.91 ADORA3 (0.58) ADORA3CSNK2A1MITFL3MBTL1CSNK2A2
SCHEMBL8740207 0.85 CSNK2A1 (0.49) CSNK2A1SMN1; SMN2MEN1ALDH1A1MAPT
SCHEMBL8279318 0.80 EGFR (0.47) CSNK2A1MAPT
SCHEMBL8279323 0.80 MEN1 (0.44) CSNK2A1MITFSMN1; SMN2KDM4EMEN1
SCHEMBL8738405 0.77 MAPT (0.58) SMN1; SMN2KDM4EMEN1ALDH1A1MAPT
SCHEMBL8528620 0.76 CSNK2A1 (0.48) CSNK2A1SMN1; SMN2MEN1ALDH1A1MAPT
SCHEMBL6118024 0.76 NPC1 (0.61) CSNK2A1SMN1; SMN2MEN1ALDH1A1KMT2A
Bromide SCHEMBL6118828 0.75 CSNK2A1 (0.48) CSNK2A1SMN1; SMN2MEN1ALDH1A1MAPT
SCHEMBL8521768 0.75 MEN1 (0.57) CSNK2A1SMN1; SMN2MEN1ALDH1A1MAPT
SCHEMBL8521250 0.74 CSNK2A1 (0.47) ADORA3CSNK2A1L3MBTL1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120129843-A1 PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129843-A1 PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION MMP1, MMP9, TIMP3 ADORA3 1491/4885CSNK2A1 2619/4885MITF 2650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.